AKOUOS
Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.
AKOUOS
Industry:
Biotechnology Health Diagnostics Pharmaceutical
Founded:
2016-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.akouos.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
162.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Global Site Tag IPv6 Google Analytics 4
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Fidelity
Fidelity investment in Series B - Akouos
PAG
PAG investment in Series B - Akouos
New Enterprise Associates
New Enterprise Associates investment in Series B - Akouos
Polaris Founders Capital
Polaris Founders Capital investment in Series B - Akouos
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Akouos
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Akouos
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series B - Akouos
RA Capital Management
RA Capital Management investment in Series B - Akouos
Surveyor Capital
Surveyor Capital investment in Series B - Akouos
Wu Capital
Wu Capital investment in Series B - Akouos
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-10 | Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer |
Official Site Inspections
http://www.akouos.com Semrush global rank: 2.96 M Semrush visits lastest month: 5.3 K
- Host name: 104.18.33.196
- IP address: 104.18.33.196
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Akouos"
About Us - Akouos
Akouos engages: honest, authentic, respectfully. Akouos leads: authentically, boldly, bravely, with purpose and passion. Akouos creates: high standards, opportunities to excel, better …See details»
Akouos - Crunchbase Company Profile & Funding
Akouos may be growing as it was acquired by Eli Lilly for $500 million, indicating a significant valuation and investment in the company's potential. The acquisition by a major …See details»
Akouos, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Akouos, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 62 news, and 9 literature, Disease Domain:Nervous System ...See details»
Akouos - Overview, News & Similar companies | ZoomInfo.com
View Akouos (www.akouos.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Akouos - Company Profile - Tracxn
Nov 15, 2024 Akouos is developing novel therapies and delivery systems to prevent hearing loss and restore hearing in genetically defined patient sub-populations. The company was selected …See details»
Our Focus – Akouos
The Akouos founding team has over 100 years of combined research experience characterizing inner ear structure-function relationships. The work of co-founder Dr. Richard J. Smith, world-renowned for his scientific and clinical expertise in …See details»
Akouos - Contacts, Employees, Board Members, Advisors & Alumni
Akouos has 8 current employee profiles, including Founder and Chief Executive Officer Manny Simons. Akouos has 5 board members and advisors, including Ed Mathers.See details»
Akouos Company Profile - Office Locations, Competitors, …
See insights on Akouos including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Akouos - Funding, Financials, Valuation & Investors
Akouos is registered under the ticker NASDAQ:AKUS . Their stock opened with $17.00 in its Jun 25, 2020 IPO. Akouos is funded by 15 investors. Fidelity and PAG are the most recent …See details»
Lilly Completes Acquisition of Akouos Expanding Efforts to Help …
INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The …See details»
Akouos - VentureRadar
"Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living …See details»
Lilly to Acquire Akouos to Discover and Develop Treatments for …
Oct 18, 2022 Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve and preserve high-acuity physiologic hearing …See details»
Akouos - workinbiotech.com
Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to …See details»
Akouos - News, Articles etc. - European Pharmaceutical Review
Oct 19, 2022 Eli Lilly and Company’s $610 million acquisition of Akouos will fast-track gene therapies that restore, improve and preserve hearing for patients worldwide.See details»
Lilly Completes Acquisition of Akouos Expanding Efforts to Help …
Dec 1, 2022 This press release contains forward-looking statements regarding Lilly's acquisition of Akouos, regarding prospective benefits of the acquisition, regarding contingent …See details»
Akouos - Updates, News, Events, Signals & Triggers
Akouos may be growing as it was acquired by Eli Lilly for $500 million, indicating a significant valuation and investment in the company's potential. The acquisition by a major …See details»
Akouos Reports Fourth Quarter and Full Year 2020 Financial …
BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Akouos,Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals …See details»
Akouos Reports Third Quarter 2022 Financial Results and Provides ...
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals …See details»
Akouos Reports Fourth Quarter and Full Year 2021 Financial …
Mar 29, 2022 About Akouos Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity …See details»